ERBB2 and breast cancer: Although estrogen receptor (ER) negative and human epidermal growth factor receptor (HER2) positive BC are associated with poor prognosis, the luminal (ER+/HER2−) tumors, which account for about 70% of all BCs [2], are clinically indeterminate.